Northwest Biotherapeutics partners with NHSBT to expand DCVax-L production
Northwest Biotherapeutics (NWBO) has partnered with the UK's National Health Service Blood and Transplant (NHSBT) to enhance the manufacturing of its experimental cancer vaccine, DCVax-L. The collaboration will support treatment for glioblastoma and other solid tumors by leveraging NHSBT’s expertise in leukapheresis and cell processing. The partnership initially involves facilities in Leeds and Oxford, with potential expansion across England. This move is expected to increase the availability of DCVax-L, a personalized immunotherapy that has shown promise but remains under clinical development.
Tickers: $NWBO
Topics: biotech cancer treatment clinical trials manufacturing partnership